Introduction
Drug tolerance can be defined as a decrease in susceptibility to the effects of a drug due to its continued administration. 1 Several hypotheses have been suggested to explain the development of tolerance. The overexpression of multidrug transporters at the blood-brain barrier is considered to be one factor in this phenomenon. 2 Based on previous data from animal experiments, many antiepileptic drugs (AEDs) have been demonstrated to be substrates for multidrug transporters and to show reduced antiepileptic efficacy due to tolerance development after repeated administration. 1 The efficacy and safety of the anti-convulsant levetiracetam (LEV), which has a novel structure and unique mechanisms of action, have been demonstrated in many clinical studies. In addition, several studies have shown sustained long-term efficacy of LEV as an add-on therapy. [3] [4] [5] [6] [7] [8] Pooled data 9 in patients with refractory epilepsy treated with LEV during the development program showed that no tolerance build up to LEV occurs. However, several animal studies have reported the development of tolerance to LEV. [10] [11] [12] A recent study using rats with chronic epilepsy revealed that LEV treatment led to effective seizure control but, despite the fact that adequate serum and brain levels of LEV were maintained, efficacy was lost within a week. 12 Incidental evidence also shows that tolerance to LEV can occur in humans; French et al. 3 have reported that the mean proportion of seizure-free days is higher in the first week of LEV treatment than in subsequent weeks, suggesting tolerance development.
It is important to further investigate whether tolerance to LEV occurs in human patients. There have been few clinical studies to date that have addressed this. In most previous studies on the efficacy of LEV, efficacy was evaluated at a certain time period without considering those patients who were initial nonresponders but became responders later. Furthermore, no discrimination between lack and loss of efficacy was performed. Accordingly, the aim of our present study was to evaluate loss of initial efficacy of LEV in adult patients with refractory partial-onset seizures.
Purpose: The efficacy and safety of the anti-convulsive drug levetiracetam (LEV) has been well documented but few clinical studies have investigated tolerance to LEV. The aim of this study was to evaluate the loss of the initial efficacy of LEV in adult patients with refractory partial-onset seizures. Methods: We enrolled patients with refractory partial epilepsy who were started on add-on LEV treatment. The efficacy of LEV was evaluated every three months and the seizure frequency was decided by the average number of monthly seizures. A responder was defined as a patient with a !50% reduction in seizure frequency from the baseline. Seizure freedom was defined as a seizure-free status from the beginning of LEV treatment to the evaluation period. Loss of the initial efficacy was defined as a shift from responder status during the first three months of LEV treatment to non-responder status during the follow-up period. Results: A total of 95 epilepsy patients were analyzed. During the first three months of LEV treatment, 50 (52.6%) of the 95 patients were responders with a !50% seizure reduction. Nine patients (18.0%) showed a loss of initial efficacy during the second three-month period. In contrast, only two (4.0%) of the nonresponders during the first three months became responders during the next three months. However, this difference did not reach statistical significance (P = 0.054). Based on Kaplan-Meier survival estimates, 49.2% of the patients who initially responded to LEV treatment during the first three months were predicted to lose this response at 42 months. Loss of the initial efficacy of LEV treatment occurred mostly within 18 months. Conclusion: This study suggests that the occurrence of tolerance is more common than late gain of efficacy of treatment although larger prospective studies would have to be carried out to prove this observation.
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Material and methods

Subjects
Patients aged at least 18 years with refractory partial epilepsy who were started on add-on LEV treatment between January 2007 and September 2010 were enrolled in this study. Subjects were included if they had been receiving one or more concomitant AEDs at stable doses for at least four weeks prior to selection, if they had uncontrolled partial seizures with or without secondary generalization at least once a month during the three-month retrospective baseline period before LEV commencement, if their epilepsy duration was at least two years from seizure onset, and if they were followed up for more than six months from LEV treatment initiation. Subjects were excluded if they had started on other AEDs simultaneously with LEV or within six months of LEV initiation, if they discontinued concomitant AED within six months of commencing LEV therapy, if they had an epilepsy surgery one year prior to commencing LEV therapy, if they had severe medical and psychiatric disorders, or if their seizure frequency could not be counted. All of the patients included in the study had been regularly monitored by one of four physicians, each a co-author of this study.
A standardized data form was developed and the data were obtained retrospectively from individual patient medical records. Variables included in the database were: age, sex, age at onset, duration of epilepsy, history of epilepsy surgery, current comorbidity, past medical history, epilepsy risk factors, number and dose of concomitant AEDs, seizure frequency, magnetic resonance imaging (MRI) results, and electroencephalographic (EEG) findings. Epilepsy and seizures were classified using the International League Against Epilepsy (ILAE) classification.
LEV treatment
The starting dose was typically 1000 mg per day, divided into two doses. The LEV dose was increased to 1500 mg or 2000 mg daily if the patient continued to experience seizures. If seizure control was not satisfactory and there were no side effects, the dose was increased to the maximum daily dose (3000 mg per day). Based on the patient's and physician's judgment, the LEV dose could be reduced or withdrawn.
Assessment
The efficacy of LEV was evaluated every three months from the beginning of treatment. The seizure frequency was decided by the average monthly seizure number during each three-month interval. A responder was defined as a patient with a !50% reduction in seizure frequency from the baseline seizure frequency at three months prior to commencing LEV. Seizure freedom was defined by a seizure-free status from the beginning of LEV treatment to the evaluation period. Loss of initial efficacy was defined as a shift from responder status during the first three months of LEV treatment to non-responder status during the follow-up period.
Statistical analysis
Statistical analysis was performed using PASW statistics 18.0 for Windows (SPSS, Chicago, IL). Parametric data are expressed as the mean AE standard deviation (SD). Comparisons between responders and non-responders groups were analyzed using binary logistic regression analysis. The difference between patients with loss of initial efficacy and gain of efficacy in the second three months was evaluated by Fisher's exact test. P values of <0.05 were considered to be statistically significant. A Kaplan-Meier survival curve was generated to analyze the loss of initial efficacy of LEV during the follow-up period.
Results
Patient characteristics
A total of 95 epilepsy patients were included in the final study cohort ( Table 1 ). The mean seizure frequency of all seizure types during the baseline period was 3.5 AE 5.3 per month. All patients were taking AEDs at baseline with 9 (9.5%) taking one AED, 43 (45.3%) taking two AEDs, 21 (22.1%) taking three AEDs and 22 (23.1%) taking four or more AEDs. The mean final LEV dose was 1373 AE 546 mg/day.
Initial LEV efficacy
During the first three months of LEV treatment, 50 (52.6%) of the 95 patients were responders with a !50% seizure reduction. Age, age at seizure onset, duration of epilepsy, baseline seizure frequency, and LEV dosage did not differ between responders and non-responders. The number of concomitant AEDs was significantly higher in non-responders (3.0 AE 1.1) than responders (2.4 AE 1.0) (P = 0.004).
Loss of initial LEV efficacy during the second three-month period
Of the 50 identified responders during the first three months, the initial efficacy of LEV was lost in 9 (18.0%) cases during the second three-month period (Fig. 1) . Age, age at seizure onset, duration of epilepsy, baseline seizure frequency, LEV dosage and number of concomitant AEDs did not differ between the response maintenance group and those that lost initial LEV efficacy. Of the 45 non-responders recorded during the first three months, only two patients became responders during the second three-month period. In both of these cases, LEV doses were increased from 1000 mg/day to 2000 mg/day at three or four months from LEV commencement. Patients with loss of initial efficacy (9/50, 18.0%) in the second three months was more common than those with gain of efficacy (2/45, 4.4%), but it did not reach statistical significance (P = 0.054).
Loss of initial LEV efficacy during the long-term follow-up period
The initial efficacy of LEV during the first three months (n = 50) was lost in 21 responders (42.0%) during the entire follow-up period. Based on Kaplan-Meier survival estimates, 49.2% of patients who initially responded to LEV treatment during first three months were predicted to lose this response at 42 months (Fig. 2) . The loss of initial LEV efficacy occurred mostly within 18 months.
Seizure freedom
Seizure freedom was obtained in 29 (30.5%) of 95 patients during the first three months. Seizure freedom was maintained during the second three-month period and the entire follow-up period in 16 (16.8%) and 7 (7.4%) patients, respectively (Fig. 1) . The proportion of seizure-free patients decreased markedly and more rapidly over time so that only 18.9% of patients who became seizure-free during the first three months of LEV treatment were predicted to maintain this response at 18 months by Kaplan-Meier survival analysis.
Change in concomitant AEDs
The number and dosage of concomitant AEDs were not changed within the first six months of LEV treatment. Subsequently, one or more concomitant AEDs were discontinued in 14 cases (34.1%) out of the 41 patients who remained responders during the first six months. Of these individuals, four patients (28.6%) became nonresponders. Loss of initial LEV efficacy was observed in 8 (29.6%) of the remaining 27 patients who did not withdraw the concomitant AEDs. Thus, the proportion that became non-responders did not differ between patients who did and did not continue taking concomitant AEDs.
Discussion
In this retrospective study we have evaluated the loss of initial efficacy of LEV in 95 adult patients with refractory partial-onset seizures. During the first 3 months of LEV treatment, 50 patients (52.6%) were responders with >50% seizure reduction. Only two non-responders during the first 3 months became responders during the next 3-month period. Initial efficacy of LEV was lost in 9 (18.0%) of 50 initial responders during the second 3-month period. (Fig. 1 ) Loss of initial efficacy of LEV treatment was predicted in up to 49.2% of patients who initially responded to LEV treatment over 42-month follow-up period and occurred mostly within 18 months of LEV treatment. (Fig. 2) Our data focusing on loss of initial efficacy of LEV is distinct from, and cannot be directly compared with, those of previous studies on the efficacy of LEV due to the fact that most previous studies used group response analysis. 1 Group response analysis between visits detects a net loss of response but may miss any loss of initial efficacy in a subgroup if the response improves over time in initial non-responders. Furthermore, in group response analysis, no discrimination is made between lack and loss of efficacy. For these reasons, group response analysis is not a reliable tool with which to assess the development of tolerance. In this study, we used individual responder analysis, which can detect an efficacy shift from responder to non-responder status in individual patients between visits. 1 In our present study, 50 of 95 patients (52.6%) were initial responders with a !50% seizure reduction during the first three months of LEV treatment. Of 50 initial responders, 9 (18.0%) showed loss of initial efficacy during the second three-month period. In contrast, only two (4.4%) non-responders during the first three months became responders during the next three months. This difference did almost reach statistical significance (P = 0.054). These data suggest that a development of tolerance to LEV occurs in patients with refractory epilepsy and contrast with the findings of a pooled-data study, 9 which showed evidence for sustained efficacy of LEV as add-on therapy in 1325 patients with refractory epilepsy treated with LEV during the development program. In this same earlier study, the proportion of responders during the first three months of LEV treatment was 39.2%. Of initial responders, 19.6% became non-responders during the second three months. However, a change of response in the opposite direction occurred in 12.0% of non-responders of the first three months who became responders during the second three-month period. Because the proportion of initial non-responders that became responders was similar to that of initial responders that became non-responders, the authors concluded that no tolerance to LEV occurs in this patient population and that the results could be accounted for by spontaneous fluctuations in seizure frequency. A decrease in the rate of seizure freedom over time may be one of the pieces of evidence that supports the idea that LEV tolerance develops in epileptic patients. In our current study, almost one-third (n = 29, 30.1%) of the total number of patients (95) became seizurefree during the first three months of LEV treatment. The rate of continued seizure freedom decreased to 16.8% (n = 16) during the second three-month period and was 7.4% (n = 7) for the entire follow-up period (Fig. 1) . These findings are consistent with previous studies. In a US multi-center study 4 of the long-term efficacy of LEV in patients with refractory partial epilepsy, the probability of remaining seizure-free for the first three months of LEV add-on treatment was 13.4%, which then declined gradually over time. By four years, the probability of remaining seizure-free from the beginning of the study was 3.7%. A single-center, prospective oneyear follow-up study 13 showed that 15 (19.0%) of 79 patients with refractory partial epilepsy were seizure-free from the start of LEV add-on therapy but four patients had a relapse after 1-3 months. The failure to remain seizure-free during the follow-up period may suggest the development of tolerance to the drug. In our present study, Kaplan-Meier analysis predicted that 49.2% of initial responders lost their initial LEV efficacy over the 42-month follow-up period and that this occurred mostly within 18 months of LEV treatment (Fig. 2) . We could not find any published data comparable to our current findings. The retention rate of treatment is considered to be a surrogate for the long-term efficacy and safety of AEDs. Therefore, a decrease in retention rate over time could be partly explained by a lack or loss of AED efficacy. In a previous retrospective three-year follow-up study 14 in patients mostly with partial epilepsy treated with LEV as adjunctive therapy or monotherapy, the retention rate was 75.2% at 12 months of LEV treatment, which then decreased to 53.7% at three years of LEV treatment. In 79.1% of the patients who discontinued LEV treatment, the treatment was discontinued due to lack or loss of efficacy. In another study 15 of 1422 patients with epilepsy exposed to LEV during its developmental program, the retention rate was estimated to be 60% after one year and 32% after five years. Of 486 withdrawals, 46.3% were due to lack or loss of efficacy. In both of these earlier studies however, no discrimination between lack and loss of efficacy was made. The exact mechanism of tolerance to LEV is unknown. LEV maintains a steady-state level in the serum without metabolism by CYP450 enzymes. 16 Hence, it is not likely that the development of tolerance to LEV would be due to pharmacokinetic interaction with concomitant AEDs. However, because LEV was recently reported to be a substrate for a multidrug transporter in humans, 17 tolerance may be associated with overexpression of multidrug transporters at the blood-brain barrier, which is considered to be a factor in the development of drug tolerance. The present study has some limitations of note. First, several confounding factors could contribute to a loss of initial efficacy of AEDs that mimics the development of tolerance to LEV. Reduced patient compliance, pharmacokinetic changes secondary to concomitant AEDs, seizure-precipitating factors (e.g., alcohol, stress, fatigue, and insufficient sleep), and an aggravating progression of the disease could be incorrectly recognized as tolerance.
1 Second, we did not evaluate the early development of tolerance to LEV in the three months of LEV treatment. For example, French et al. 3 reported that the mean proportion of seizure-free days in patients with refractory epilepsy was higher in the first week of LEV treatment compared with the following weeks, indicating development of tolerance to LEV in the course of a few weeks. Third, there were methodological limitations. We used individual responder analysis to evaluate loss of initial efficacy, 1 but this method also cannot exclude 'the effect of regression to the mean'. 18 In addition, the group sizes in this study
were not big enough for showing a significant effect. Sample size was estimated using power-based sample size calculations. A sample size of at least 77 patients in both groups (responders/nonresponders) would have been needed to achieve a significance level of <0.05 at a power of 80%.
In conclusion, our study suggests that the occurrence of tolerance is more common than late gain of efficacy of treatment although larger prospective studies would have to be carried out to prove this observation.
